Transdermal Drug Delivery Systems Market By Type Of Delivery System (Passive, Active), By Application (Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global transdermal drug delivery systems market size was valued at $52,476.5 million in 2020, and is projected to reach $87,322.4 million by 2030, registering a CAGR of 4.9% from 2021 to 2030. Transdermal drug delivery systems are dosage forms that are designed to deliver an effective amount of drug across a patient's skin. The adhesive used in transdermal drug delivery systems govern the safety, efficiency, and quality of the product.
Transdermal drug delivery systems are capable of maintaining adequate concentration of medicine in the blood for a long period of time. These systems can also reduce the chances of systemic adverse reactions, such as gastrointestinal tract disorders.
The increase in number of patients suffering from chronic diseases, such as heart diseases, diabetes, and arthritis has significantly increased owing to lifestyle changes and stressful work culture. Furthermore, the global geriatric population is also on the rise. These factors positively influence the growth of the market. However, side-effects caused by the use of transdermal drug delivery systems can restraint the market growth. Advancements in technologies enable the use of transdermal systems for delivering a wide range of drugs.
The transdermal drug delivery systems market is segmented on the basis of type of delivery, application, and region. By type of delivery, the market is classified into passive and active.. By application, it is categorized into analgesics, hormone replacement therapy, hypertension, motion sickness, smoking cessation and others . By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market
COMPETITION ANALYSIS
The major market participants profiled in this report include Altaris, Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Novartis AG, Purdue Pharma L.P. and Viatris Inc.
KEY BENEFITS FOR STAKEHOLDERS
The report provides an extensive analysis of the current and emerging transdermal drug delivery systems market trends and dynamics.
In-depth market analysis is conducted by constructing market estimations for the key market segments between 2020 and 2030.
Extensive analysis of the transdermal drug delivery systems market is conducted by following key product positioning and monitoring of the top competitors within the market framework.
A comprehensive analysis of all regions is provided to determine the prevailing opportunities.
The global transdermal drug delivery systems market forecast analysis from 2021 to 2030 is included in the report.
The key market players within transdermal drug delivery systems market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the transdermal drug delivery systems industry.
Key Market Segments
By BY TYPE OF DELIVERY SYSTEM
Passive
Active
By BY APPLICATION
Analgesics
Hormone Replacement Therapies
Hypertension
Motion Sickness
Smoking Cessation
Others
By BY REGION
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
North America
U.S
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Key Market Players
Viatris Inc.
Bayer AG
Boehringer Ingelheim GmbH
Endo International plc
GlaxoSmithKline plc
Johnson & Johnson
Novartis AG
Purdue Pharma L.P.
Altaris
Hisamitsu Pharmaceutical Co. Inc.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Passive
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Active
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Analgesics
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Hormone Replacement Therapies
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Hypertension
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Motion Sickness
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Smoking Cessation
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 Others
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- CHAPTER 6: TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Asia-Pacific
- 6.2.1 Key trends and opportunities
- 6.2.2 Asia-Pacific Market size and forecast, by Type Of Delivery System
- 6.2.3 Asia-Pacific Market size and forecast, by Application
- 6.2.4 Asia-Pacific Market size and forecast, by country
- 6.2.4.1 Japan
- 6.2.4.1.1 Market size and forecast, by Type Of Delivery System
- 6.2.4.1.2 Market size and forecast, by Application
- 6.2.4.2 China
- 6.2.4.2.1 Market size and forecast, by Type Of Delivery System
- 6.2.4.2.2 Market size and forecast, by Application
- 6.2.4.3 India
- 6.2.4.3.1 Market size and forecast, by Type Of Delivery System
- 6.2.4.3.2 Market size and forecast, by Application
- 6.2.4.4 Australia
- 6.2.4.4.1 Market size and forecast, by Type Of Delivery System
- 6.2.4.4.2 Market size and forecast, by Application
- 6.2.4.5 South Korea
- 6.2.4.5.1 Market size and forecast, by Type Of Delivery System
- 6.2.4.5.2 Market size and forecast, by Application
- 6.2.4.6 Rest of Asia-Pacific
- 6.2.4.6.1 Market size and forecast, by Type Of Delivery System
- 6.2.4.6.2 Market size and forecast, by Application
- 6.3 LAMEA
- 6.3.1 Key trends and opportunities
- 6.3.2 LAMEA Market size and forecast, by Type Of Delivery System
- 6.3.3 LAMEA Market size and forecast, by Application
- 6.3.4 LAMEA Market size and forecast, by country
- 6.3.4.1 Brazil
- 6.3.4.1.1 Market size and forecast, by Type Of Delivery System
- 6.3.4.1.2 Market size and forecast, by Application
- 6.3.4.2 Saudi Arabia
- 6.3.4.2.1 Market size and forecast, by Type Of Delivery System
- 6.3.4.2.2 Market size and forecast, by Application
- 6.3.4.3 South Africa
- 6.3.4.3.1 Market size and forecast, by Type Of Delivery System
- 6.3.4.3.2 Market size and forecast, by Application
- 6.3.4.4 Rest of LAMEA
- 6.3.4.4.1 Market size and forecast, by Type Of Delivery System
- 6.3.4.4.2 Market size and forecast, by Application
- 6.4 North America
- 6.4.1 Key trends and opportunities
- 6.4.2 North America Market size and forecast, by Type Of Delivery System
- 6.4.3 North America Market size and forecast, by Application
- 6.4.4 North America Market size and forecast, by country
- 6.4.4.1 U.S.
- 6.4.4.1.1 Market size and forecast, by Type Of Delivery System
- 6.4.4.1.2 Market size and forecast, by Application
- 6.4.4.2 Canada
- 6.4.4.2.1 Market size and forecast, by Type Of Delivery System
- 6.4.4.2.2 Market size and forecast, by Application
- 6.4.4.3 Mexico
- 6.4.4.3.1 Market size and forecast, by Type Of Delivery System
- 6.4.4.3.2 Market size and forecast, by Application
- 6.5 Europe
- 6.5.1 Key trends and opportunities
- 6.5.2 Europe Market size and forecast, by Type Of Delivery System
- 6.5.3 Europe Market size and forecast, by Application
- 6.5.4 Europe Market size and forecast, by country
- 6.5.4.1 Germany
- 6.5.4.1.1 Market size and forecast, by Type Of Delivery System
- 6.5.4.1.2 Market size and forecast, by Application
- 6.5.4.2 France
- 6.5.4.2.1 Market size and forecast, by Type Of Delivery System
- 6.5.4.2.2 Market size and forecast, by Application
- 6.5.4.3 U.K.
- 6.5.4.3.1 Market size and forecast, by Type Of Delivery System
- 6.5.4.3.2 Market size and forecast, by Application
- 6.5.4.4 Italy
- 6.5.4.4.1 Market size and forecast, by Type Of Delivery System
- 6.5.4.4.2 Market size and forecast, by Application
- 6.5.4.5 Spain
- 6.5.4.5.1 Market size and forecast, by Type Of Delivery System
- 6.5.4.5.2 Market size and forecast, by Application
- 6.5.4.6 Rest of Europe
- 6.5.4.6.1 Market size and forecast, by Type Of Delivery System
- 6.5.4.6.2 Market size and forecast, by Application
- CHAPTER 7: COMPANY LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Key developments
- CHAPTER 8: COMPANY PROFILES
- 8.1 Viatris Inc.
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
- 8.2 Bayer AG
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
- 8.3 Boehringer Ingelheim GmbH
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
- 8.4 Endo International plc
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
- 8.5 GlaxoSmithKline plc
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
- 8.6 Johnson & Johnson
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
- 8.7 Novartis AG
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
- 8.8 Purdue Pharma L.P.
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
- 8.9 Altaris
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
- 8.10 Hisamitsu Pharmaceutical Co. Inc.
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
- TABLE 2. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR PASSIVE, BY REGION , 2020-2030,($MILLION)
- TABLE 3. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET PASSIVE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR ACTIVE, BY REGION , 2020-2030,($MILLION)
- TABLE 5. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET ACTIVE BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 7. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR ANALGESICS, BY REGION , 2020-2030,($MILLION)
- TABLE 8. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET ANALGESICS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 9. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR HORMONE REPLACEMENT THERAPIES, BY REGION , 2020-2030,($MILLION)
- TABLE 10. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET HORMONE REPLACEMENT THERAPIES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 11. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR HYPERTENSION, BY REGION , 2020-2030,($MILLION)
- TABLE 12. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET HYPERTENSION BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR MOTION SICKNESS, BY REGION , 2020-2030,($MILLION)
- TABLE 14. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET MOTION SICKNESS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 15. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR SMOKING CESSATION, BY REGION , 2020-2030,($MILLION)
- TABLE 16. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SMOKING CESSATION BY COUNTRY, 2020-2030,($MILLION)
- TABLE 17. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 18. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 19. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 20. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
- TABLE 21. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 22. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 23. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 24. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 25. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 26. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 27. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 28. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 29. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 30. AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 31. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 32. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 33. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 34. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 35. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
- TABLE 36. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 37. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 38. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 39. BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 40. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 41. SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 42. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 43. SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 44. REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 45. REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 46. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
- TABLE 47. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 48. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 49. U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 50. U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 51. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 52. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 53. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 54. MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 55. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF DELIVERY SYSTEM, 2020-2030,($MILLION)
- TABLE 56. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 57. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 58. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 59. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 60. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 61. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 62. U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 63. U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 64. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 65. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 66. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 67. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 68. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY TYPE OF DELIVERY SYSTEM 2020-2030,($MILLION)
- TABLE 69. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 70.VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 71.VIATRIS INC.: OPERATING SEGMENTS
- TABLE 72.VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 73.VIATRIS INC.: NET SALES,
- TABLE 74.VIATRIS INC.: KEY STRATERGIES
- TABLE 75.BAYER AG: COMPANY SNAPSHOT
- TABLE 76.BAYER AG: OPERATING SEGMENTS
- TABLE 77.BAYER AG: PRODUCT PORTFOLIO
- TABLE 78.BAYER AG: NET SALES,
- TABLE 79.BAYER AG: KEY STRATERGIES
- TABLE 80.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
- TABLE 81.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
- TABLE 82.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
- TABLE 83.BOEHRINGER INGELHEIM GMBH: NET SALES,
- TABLE 84.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
- TABLE 85.ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT
- TABLE 86.ENDO INTERNATIONAL PLC: OPERATING SEGMENTS
- TABLE 87.ENDO INTERNATIONAL PLC: PRODUCT PORTFOLIO
- TABLE 88.ENDO INTERNATIONAL PLC: NET SALES,
- TABLE 89.ENDO INTERNATIONAL PLC: KEY STRATERGIES
- TABLE 90.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 91.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 92.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 93.GLAXOSMITHKLINE PLC: NET SALES,
- TABLE 94.GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 95.JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 96.JOHNSON & JOHNSON: OPERATING SEGMENTS
- TABLE 97.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 98.JOHNSON & JOHNSON: NET SALES,
- TABLE 99.JOHNSON & JOHNSON: KEY STRATERGIES
- TABLE 100.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 101.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 102.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 103.NOVARTIS AG: NET SALES,
- TABLE 104.NOVARTIS AG: KEY STRATERGIES
- TABLE 105.PURDUE PHARMA L.P.: COMPANY SNAPSHOT
- TABLE 106.PURDUE PHARMA L.P.: OPERATING SEGMENTS
- TABLE 107.PURDUE PHARMA L.P.: PRODUCT PORTFOLIO
- TABLE 108.PURDUE PHARMA L.P.: NET SALES,
- TABLE 109.PURDUE PHARMA L.P.: KEY STRATERGIES
- TABLE 110.ALTARIS: COMPANY SNAPSHOT
- TABLE 111.ALTARIS: OPERATING SEGMENTS
- TABLE 112.ALTARIS: PRODUCT PORTFOLIO
- TABLE 113.ALTARIS: NET SALES,
- TABLE 114.ALTARIS: KEY STRATERGIES
- TABLE 115.HISAMITSU PHARMACEUTICAL CO. INC.: COMPANY SNAPSHOT
- TABLE 116.HISAMITSU PHARMACEUTICAL CO. INC.: OPERATING SEGMENTS
- TABLE 117.HISAMITSU PHARMACEUTICAL CO. INC.: PRODUCT PORTFOLIO
- TABLE 118.HISAMITSU PHARMACEUTICAL CO. INC.: NET SALES,
- TABLE 119.HISAMITSU PHARMACEUTICAL CO. INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION
- FIGURE 2.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030
- FIGURE 3.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,BY TYPE OF DELIVERY SYSTEM,2020(%)
- FIGURE 12.COMPARATIVE SHARE ANALYSIS OF PASSIVE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACTIVE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 14.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,BY APPLICATION,2020(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANALGESICS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HORMONE REPLACEMENT THERAPIES TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HYPERTENSION TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SMOKING CESSATION TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030(%)
- FIGURE 21.TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET BY REGION,2020
- FIGURE 22.JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 23.CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 24.INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 25.AUSTRALIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 26.SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 27.REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 28.BRAZIL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 29.SAUDI ARABIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 30.SOUTH AFRICA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 31.REST OF LAMEA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 32.U.S. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 33.CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 34.MEXICO TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 35.GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 36.FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 37.U.K. TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 38.ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 39.SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 40.REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET,2020-2030($MILLION)
- FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 45.COMPETITIVE DASHBOARD
- FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 47.VIATRIS INC..: NET SALES ,($MILLION)
- FIGURE 48.BAYER AG.: NET SALES ,($MILLION)
- FIGURE 49.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
- FIGURE 50.ENDO INTERNATIONAL PLC.: NET SALES ,($MILLION)
- FIGURE 51.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
- FIGURE 52.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
- FIGURE 53.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 54.PURDUE PHARMA L.P..: NET SALES ,($MILLION)
- FIGURE 55.ALTARIS.: NET SALES ,($MILLION)
- FIGURE 56.HISAMITSU PHARMACEUTICAL CO. INC..: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook